Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M68.9Revenue (TTM) $M15.3Net Margin (%)-72.6Altman Z-Score-9.7
Enterprise Value $M63.2EPS (TTM) $-0.6Operating Margin %-63.2Piotroski F-Score6
P/E(ttm)--Beneish M-Score0.2Pre-tax Margin (%)-72.6Higher ROA y-yY
Price/Book21.410-y EBITDA Growth Rate %--Quick Ratio2.2Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-15.2Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-294.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.3ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NBY is held by these investors:



NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-61.7view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-70view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-70view
Najafi RaminChairman 2015-03-03Buy6,667$15-70view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-72.31view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-73.53view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-72.73view
Najafi RaminChairman 2014-12-11Buy800$15-70view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-73.13view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-72.31view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
Novabay Pharmaceuticals' CEO Dr. Ramin Najafi Interviewed by The Life Sciences Report Jun 25 2015 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
NovaBay Pharmaceuticals Receives Notification of Noncompliance with Additional NYSE American... Sep 20 2017
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : September 19, 2017 Sep 19 2017
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18,... Sep 18 2017
Eye Surgeon Says Keep Eyelids Healthy with Avenova from NovaBay Sep 18 2017
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017
NovaBay's Avenova Offers Key Benefits in Glaucoma Care Aug 14 2017
NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 10 2017
Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call Aug 10 2017
NovaBay Pharmaceuticals to Hold 2017 Second Quarter Conference Call on August 10, 2017 Aug 03 2017
Fighting Parasitic Eyelid Mites with Avenova from NovaBay Pharmaceuticals Jul 24 2017
UPDATE: NovaBay's Avenova Highlighted in National Dry Eye Awareness Month Jul 10 2017
NovaBay's Avenova Highlighted in National Dry Eye Awareness Month Jul 10 2017
NovaBay Pharmaceuticals Announces CFO Transition Jul 10 2017
NovaBay Pharmaceuticals Joins the Russell Microcap Index Jun 26 2017
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017 Jun 13 2017
NovaBay Pharmaceuticals to Present at the 7th Annual LD Micro Invitational May 30 2017
NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT May 19 2017
NovaBay Pharmaceuticals Reports First Quarter 2017 Financial Results May 11 2017
NovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017 May 04 2017
Avenova from NovaBay Pharmaceuticals is Effective for Managing Dry Eye before Refractive and... May 02 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}